A Case of Multiple Myeloma with Atypical Cutaneous Presentation Treated by Daratumumab + CYBORG

IF 1.8 Q3 HEMATOLOGY

Hematology, Transfusion and Cell Therapy Pub Date : 2024-05-01 DOI:10.1016/j.htct.2024.04.017

Bengisu Ece DUMAN , Candas MUMCU , Berra Nur ISCI , Emre BAL , Meryem SENER , Hande Yanar , Arbil ACIKALIN , Birol GUVENC

{"title":"A Case of Multiple Myeloma with Atypical Cutaneous Presentation Treated by Daratumumab + CYBORG","authors":"Bengisu Ece DUMAN , Candas MUMCU , Berra Nur ISCI , Emre BAL , Meryem SENER , Hande Yanar , Arbil ACIKALIN , Birol GUVENC","doi":"10.1016/j.htct.2024.04.017","DOIUrl":null,"url":null,"abstract":"<div><p>This case report illustrates the unconventional progression of multiple myeloma (MM) in a 57-year-old male, primarily highlighted by a cutaneous manifestation on the right cheek malar region, indicative of disease recurrence. Initially diagnosed following back pain and dyspnea, the patient's journey took a distinctive path from standard multiple myeloma treatments to the innovative application of daratumumab + CYBORG therapy. The biopsy from the lesion confirmed the recurrence of plasma cell neoplasia, leading to the adoption of daratumumab + CYBORG therapy. This innovative treatment strategy underscores the evolving landscape of MM management, particularly in cases presenting with atypical symptoms such as cutaneous involvement. The implementation of daratumumab + CYBORG therapy in this context not only highlights its potential as a significant advancement in MM treatment.</p></div>","PeriodicalId":12958,"journal":{"name":"Hematology, Transfusion and Cell Therapy","volume":null,"pages":null},"PeriodicalIF":1.8000,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2531137924000993/pdfft?md5=db9e70153ef4ae198bceed14bdd02f75&pid=1-s2.0-S2531137924000993-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hematology, Transfusion and Cell Therapy","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2531137924000993","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

This case report illustrates the unconventional progression of multiple myeloma (MM) in a 57-year-old male, primarily highlighted by a cutaneous manifestation on the right cheek malar region, indicative of disease recurrence. Initially diagnosed following back pain and dyspnea, the patient's journey took a distinctive path from standard multiple myeloma treatments to the innovative application of daratumumab + CYBORG therapy. The biopsy from the lesion confirmed the recurrence of plasma cell neoplasia, leading to the adoption of daratumumab + CYBORG therapy. This innovative treatment strategy underscores the evolving landscape of MM management, particularly in cases presenting with atypical symptoms such as cutaneous involvement. The implementation of daratumumab + CYBORG therapy in this context not only highlights its potential as a significant advancement in MM treatment.

查看原文本刊更多论文

达拉单抗+CYBORG治疗伴有非典型皮肤表现的多发性骨髓瘤病例

本病例报告展示了一名 57 岁男性多发性骨髓瘤（MM）的非常规进展，主要突出表现为右颊颊区的皮肤表现，表明疾病复发。患者最初因背部疼痛和呼吸困难而被确诊，从标准的多发性骨髓瘤治疗到达拉单抗+CYBORG疗法的创新应用，患者的病程经历了一条与众不同的道路。病灶活检证实浆细胞瘤复发，因此采用了达拉单抗+CYBORG疗法。这一创新治疗策略凸显了 MM 治疗的不断发展，尤其是在出现皮肤受累等非典型症状的病例中。在这种情况下采用达拉单抗+CYBORG疗法，不仅凸显了其作为MM治疗领域重大进展的潜力，而且还为MM患者提供了一种新的治疗方法。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊